Nohla Therapeutics Announces Second Closing of $56 Million Series B Financing
SEATTLE, July 11, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, today announced the second closing of its Series B financing, bringing the total amount raised in this round to $56 million. New investors participating in the second closing included the University of Tokyo Edge Capital, Schroder Adveq and Premier Partners. They joined the initial Series B investor syndicate of Fidelity Management and Research Company, Celgene Corporation, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.
“We are pleased to add these key, international investors to an already strong syndicate of Series B investors,” said Katie Fanning, President and CEO of Nohla Therapeutics. “We have achieved a number of significant milestones in the first half of 2018 including further advancement of our lead product, dilanubicel. This additional funding will support our ongoing clinical development of dilanubicel in allogeneic transplant and acute myeloid leukemia, as well as support the advancement of discovery programs from our platform.”
About DilanubicelDilanubicel is a universal, off-the-shelf stem and progenitor cell therapy designed to provide short-term bone marrow function, while also providing long term immunologic benefits with the potential for improved survival. Dilanubicel is currently the subject of two ongoing Phase 2 trials for patients with hematologic malignancies undergoing an allogeneic transplant, and acute myeloid leukemia (AML) patients with chemotherapy-induced myelosuppression following high-dose chemotherapy.
About Nohla TherapeuticsNohla Therapeutics is a leading developer of universal, off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla’s proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company’s lead product candidate, dilanubicel, is currently under evaluation in two ongoing Phase 2 trials. Nohla is also pursuing multiple preclinical and discovery programs focused on immune modulation and induction, genetically-modified stem cells for gene therapy and editing, and CAR progenitor and NK cell therapies. More information is available at www.nohlatherapeutics.com.
Nohla Contact:Jim DeNikeSenior Director, Corporate Development & Investor Relations206.519.5294 email@example.com